✦ LIBER ✦

Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis

✍ Scribed by Eiji Mori; Mayumi Thomas; Kazuhiro Motoki; Shiro Kataoka

Book ID: 116466006
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 95 KB
Volume: 579
Category: Article
ISSN: 0014-5793
DOI: 10.1016/j.febslet.2005.09.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The histone deacetylase inhibitor suberi

The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis

✍ Xu Dong Zhang; Susan K. Gillespie; Jodie M. Borrow; Peter Hersey 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 207 KB

The Tumor Necrosis Factor-related Apopto

The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation

✍ Muhlenbeck, F.; Schneider, P.; Bodmer, J.-L.; Schwenzer, R.; Hauser, A.; Schuber 📂 Article 📅 2000 🏛 The American Society for Biochemistry and Molecula 🌐 English ⚖ 404 KB

Activity of selective fully human agonis

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

✍ Georgios V. Georgakis; Yang Li; Robin Humphreys; Michael Andreeff; Susan O'Brien 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB

197 A phase I and pharmacokinetic (PK) s

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

✍ J. de Bono; G. Attard; R. Plummer; S. Pacey; C. Bale; L. Vidal; A. Greystoke; N. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Phase II trial of mapatumumab, a fully h

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

✍ Trarbach, T; Moehler, M; Heinemann, V; Köhne, C-H; Przyborek, M; Schulz, C; Snel 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 318 KB

208 HGS-ETR1, a fully human monoclonal a

208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial

✍ S.J. Hotte; A.M. Oza; L.H. Le; M. MacLean; A. Iacobucci; A. Corey; N.L. Fox; H.W 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB